Actively Recruiting
A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours
Led by Chris Goodman · Updated on 2026-02-04
141
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new approach to palliative radiation therapy for patients with intrathoracic tumors related to lung cancers. This study compares standard thoracic radiation therapy with a specialized technique called hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy (IMRT). The goal is to see if this advanced radiation method can safely deliver higher doses to tumors while reducing side effects, potentially improving quality of life and survival. Participants will be randomly assigned to receive either the standard radiation therapy, which involves 20 Gray in 5 fractions or 30 Gray in 10 fractions, or the experimental hypofractionated radiation therapy delivering 35 Gray in 5 fractions. Both treatments use advanced planning techniques to target tumors while sparing the esophagus. The study allows concurrent systemic treatments and radiotherapy to other metastatic sites as deemed appropriate by the treating physicians. During the study, participants will be monitored from enrollment until 36 months after radiotherapy. Researchers will assess the time until significant quality of life decline or death, patient-reported quality of life outcomes, treatment-related side effects, tumor progression within the thorax, and overall survival. Follow-up visits will track these outcomes to understand the impact of the different radiation approaches on patient well-being and disease control.
CONDITIONS
Brief Title
An Evaluation of Dose-escalation for Intrathoracic Tumours
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Intrathoracic tumor requiring palliative radiation for symptom relief or prevention of symptoms expected within 6 months
- Willingness and ability to provide informed consent
- Eastern Cooperative Oncology Group performance status between 0 and 3
- Age 18 years or older
- Prior or planned systemic treatment allowed as decided by medical oncologist
- Concurrent palliative radiotherapy to other metastatic sites allowed as decided by radiation oncologist
- Life expectancy greater than 3 months
You will not qualify if you...
- Prior thoracic radiotherapy that prevents further thoracic radiation according to treating radiation oncologist
- Serious medical conditions, including interstitial lung disease, that prevent radiation therapy
- Pregnant or lactating women
- Inability to attend full radiotherapy course or planned follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 2 weeks depending on radiation schedule
Participants receive hypofractionated or standard palliative thoracic radiation therapy to manage intrathoracic tumors.
5 to 10 treatment visits depending on assigned radiation regimen
Duration - Up to 36 months post radiotherapy
Participants are monitored for quality of life, adverse events, tumor progression, and overall survival after radiation therapy.
Regular follow-up visits during 36 months post-treatment
Trial Site Locations
Total: 3 locations
1
British Columbia Cancer Agency Center for the Southern Interior
Kelowna, British Columbia, Canada, V1Y5L3
Actively Recruiting
2
London Health Sciences Center Research Institute (Formerly Lawson Research Institute)
London, Ontario, Canada, N6A 4L6
Actively Recruiting
3
Waterloo Regional Health Network
Waterloo, Ontario, Canada
Actively Recruiting
Research Team
C
Christopher Goodman, MD
D
David Palma, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here